Saccharomyces

Biocodex Celebrates 100 Years of Saccharomyces boulardii CNCM I-745 Yeast-Based Probiotic Strain

Retrieved on: 
Thursday, June 22, 2023
Extrapyramidal system, Diarrhea, Saccharomyces boulardii, Medical science liaison, BSN, Science, Future, CNCM, RN, Health, Probiotic, Medical education, Skin, Dietary supplement, Beer, Saccharomyces

BEDMINSTER, N.J., June 22, 2023 /PRNewswire-PRWeb/ -- Saccharomyces boulardii CNCM I-745, the first yeast-based probiotic strain discovered in 1923 by French microbiologist Henri Boulard and first commercialized by Biocodex Inc., maker of the Florastor®, the only probiotic that contains this exclusive strain, represents a century of probiotic pioneering, scientific advancements, and positive impact on human health. As this unique strain celebrates 100 years, the company has its eyes set on the future of the science of the microbiome and new discoveries to support common occasional health issues.

Key Points: 
  • As this unique strain celebrates 100 years, the company has its eyes set on the future of the science of the microbiome and new discoveries to support common occasional health issues.
  • "The strain, Saccharomyces boulardii CNCM I-745 has a rich, scientific history.
  • Saccharomyces boulardii CNCM I-745, a unique yeast strain, was first discovered by Boulard during his travels in Southeast Asia.
  • "This drink was found to have a single, specific yeast strain that he called Saccharomyces boulardii."

Cytovance Biologics and Phenotypeca Collaborate to Enhance Saccharomyces cerevisiae Strain Development for Microbial Biomanufacturing

Retrieved on: 
Saturday, March 11, 2023
Research, Knowledge, API, Fermentation, CDMO, FDA, Saccharomyces cerevisiae, Protein, Fine chemical, Saccharomyces

The collaboration between Cytovance Biologics and Phenotypeca is expected to accelerate the development of high-performance yeast strains and to improve the efficiency of biologics production for biopharma clients by leveraging Cytovance Biologics’s extensive knowledge in microbial fermentation and Phenotypeca’s yeast strain development technology to produce high quality expressing cell lines.

Key Points: 
  • The collaboration between Cytovance Biologics and Phenotypeca is expected to accelerate the development of high-performance yeast strains and to improve the efficiency of biologics production for biopharma clients by leveraging Cytovance Biologics’s extensive knowledge in microbial fermentation and Phenotypeca’s yeast strain development technology to produce high quality expressing cell lines.
  • This collaboration extends Cytovance Biologics’ leadership in manufacturing microbial-derived active pharmaceutical ingredients (API) from end to end and expands Phenotypeca’s commercial reach.
  • "This collaboration is an exciting opportunity to leverage Phenotypeca’s expertise in yeast strain development to enhance our microbial capabilities.
  • We look forward to working with Phenotypeca to develop high-performance Saccharomyces cerevisiae strains and advance the biologic through product lifecycle,” said Ping Zhang, CEO of Cytovance Biologics.

Specialty Yeast Market by Type, Species, Application and Region - Global Forecast to 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, October 21, 2022
Retail, Agriculture, Natural Resources, Food, Beverage, Saccharomyces, Urbanization, Efficiency, Growth, Ministry of Health & Wellness, Taste, Saccharomyces cerevisiae, CAGR, Food industry, Wine, Region, Awareness, Food, Fermentation, USD, Beer, Kluyveromyces

The "Global Specialty Yeast Market by Type (Yeast Extracts, Yeast Autolysates, Yeast Beta-glucan, Other Yeast Derivatives), Species (Saccharomyces Cerevisiae, Pichia Pastoris, Kluyveromyces), Application and Region - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Specialty Yeast Market by Type (Yeast Extracts, Yeast Autolysates, Yeast Beta-glucan, Other Yeast Derivatives), Species (Saccharomyces Cerevisiae, Pichia Pastoris, Kluyveromyces), Application and Region - Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
  • The global specialty yeast market is estimated to be valued at USD 3.2 billion in 2022.
  • The market is gaining momentum as specialty yeast products continue to find increased applications across food, beverage, feed and other industries.
  • Additionally, the rising innovation in the specialty yeast market and rising consumer awareness regarding natural ingredients and to pursue ingredients with multiple functional abilities have contributed to the growth of specialty yeast market in recent years.

Global Yeast Extracts and Beta-Glucan Market (2022 to 2028) - Size, Share & Industry Trends Analysis Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022
Organic Food, Retail, Health, Fitness & Nutrition, Vitamins, Supplements, Food, Beverage, CAGR, Animal, Carbon, Dizziness, Saccharomyces, Dietary fiber, Saccharomyces cerevisiae, Soil, Yeast, Bread, Plant, Adoption, Hyperglycemia, Growth, Insulin, Weakness, Health, Diabetes, Hypoglycemia, Fungus, Bacteria, Food, Beta-glucan, Application, Patient, Cell, Beer, Fermentation, Wine, Dietary supplement

The "Global Yeast Extracts and Beta-Glucan Market By Type (Yeast Extract and Yeast Beta-Glucan), By Application, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Yeast Extracts and Beta-Glucan Market By Type (Yeast Extract and Yeast Beta-Glucan), By Application, By Regional Outlook and Forecast, 2022 - 2028" report has been added to ResearchAndMarkets.com's offering.
  • The Global Yeast Extracts and Beta-Glucan Market size is expected to reach $2.3 billion by 2028, rising at a market growth of 7.9% CAGR during the forecast period.
  • Yeast extract is a culinary flavor that is made with the same yeast that is utilized in the production of bread and beer.
  • Yeast extracts are sophisticated yeast hydrolysates that are commonly being employed in the food and beverage industry all over the world.

NASA Selects New Instruments for Priority Artemis Science on Moon

Retrieved on: 
Thursday, June 2, 2022
University, Science, Saccharomyces cerevisiae, PRISM, Biology, Ames Research Center, International Space Station, Langley Research Center, DNA repair, LEIA, CLPS, Silicon, CubeSat, International Space Orchestra, Multimedia, NASA, Genetics, Artemis, Saccharomyces, DNA, Johnson Space Center, Radiation, Payload, View, Central Florida, Commercial Lunar Payload Services, Science Mission Directorate, Communications satellite, Moon

These payload suites mark the second selection through the agency's Payloads and Research Investigations on the Surface of the Moon (PRISM) call for proposals.

Key Points: 
  • These payload suites mark the second selection through the agency's Payloads and Research Investigations on the Surface of the Moon (PRISM) call for proposals.
  • "The two selected studies will address important scientific questions related to the Moon" said Joel Kearns, deputy associate administrator for exploration in NASA's Science Mission Directorate.
  • "The first will study geologic processes of early planetary bodies that are preserved on the Moon, by investigating a rare form of lunar volcanism.
  • The science and technology payloads sent to the Moon's surface will help lay the foundation for human missions on and around the Moon.

Angel Yeast's Patented Probiotic S. boulardii Alleviates Common IBD Symptoms, New Research Shows

Retrieved on: 
Wednesday, February 9, 2022
Prevalence, Trial of the century, S, Huazhong University of Science and Technology, Diet, Degenerative disease, Technology, Inflammatory bowel disease, Research, Powder, Saccharomyces, Capsule, Chocolate, Incidence, Saccharomyces boulardii, Probiotic, Digestion, Patient, Gastric acid, Phenotype, Huachung University, Typical, Health, Tablet, Steroid, Therapy, IBD, DSS, Diarrhea, International Foundation, Food, Antibody, Dietary supplement

The results of the study show that the patented yeast-based probiotic developed by Angel Yeast plays a beneficial role in addressing the symptoms of IBD.

Key Points: 
  • The results of the study show that the patented yeast-based probiotic developed by Angel Yeast plays a beneficial role in addressing the symptoms of IBD.
  • Data from the International Foundation for Gastrointestinal Disorders (IFGD) reveals that IBD is the most common functional gastrointestinal disorder and affects between 10-15% of the global population.
  • [1] Typical medical treatments for IBD include antibodies, steroids and immunomodulators; however, these have low efficacy and a high incidence of recurrence.
  • S. boulardii was developed by Angel Yeast to address problems with diarrhea, one of the most common symptoms of IBD,[3] and improve overall digestive health.

Angel Yeast's Patented Probiotic S. boulardii Alleviates Common IBD Symptoms, New Research Shows

Retrieved on: 
Wednesday, February 9, 2022
Prevalence, Trial of the century, S, Huazhong University of Science and Technology, Diet, Degenerative disease, Technology, Inflammatory bowel disease, Research, Powder, Saccharomyces, Capsule, Chocolate, Incidence, Saccharomyces boulardii, Probiotic, Digestion, Patient, Gastric acid, Phenotype, Huachung University, Typical, Health, Tablet, Steroid, Therapy, IBD, DSS, Diarrhea, International Foundation, Food, Antibody, Dietary supplement

The results of the study show that the patented yeast-based probiotic developed by Angel Yeast plays a beneficial role in addressing the symptoms of IBD.

Key Points: 
  • The results of the study show that the patented yeast-based probiotic developed by Angel Yeast plays a beneficial role in addressing the symptoms of IBD.
  • Data from the International Foundation for Gastrointestinal Disorders (IFGD) reveals that IBD is the most common functional gastrointestinal disorder and affects between 10-15% of the global population.
  • [1] Typical medical treatments for IBD include antibodies, steroids and immunomodulators; however, these have low efficacy and a high incidence of recurrence.
  • S. boulardii was developed by Angel Yeast to address problems with diarrhea, one of the most common symptoms of IBD,[3] and improve overall digestive health.

Global Probiotics in Animal Feed Market Report and Forecast to 2026: A USD 7.3 Billion Market by 2026 - ResearchAndMarkets.com

Retrieved on: 
Monday, September 6, 2021
Retail, Agriculture, Natural Resources, Food, Beverage

The global probiotics in animal feed in animal feed market was valued at USD 4.4 billion in 2020.

Key Points: 
  • The global probiotics in animal feed in animal feed market was valued at USD 4.4 billion in 2020.
  • It is estimated to reach about USD 4.8 billion in 2021 and is projected to grow at a CAGR of 8.8%, to reach USD 7.3 billion by 2026.
  • The industrialization of the animal industry is one of the reasons for the increasing demand for probiotics in animal feed.
  • The stringent regulations for probiotics in animal feed products to meet the international quality standards is acting as the major restraint.

Angel Yeast Launches Patented Saccharomyces Boulardii Bld-3, a Strain of Yeast Probiotic Effective Against Diarrhea

Retrieved on: 
Thursday, September 2, 2021
CTO, Diarrhea, Saccharomyces cerevisiae, Chinese Journal, COVID-19, Gastroenteritis, Saccharomyces, Gastric acid, Probiotic, Angel, Human, Enzyme, Saccharomyces boulardii, Adult, Biofuel, Google Trends, Gastroenterology, Health, Dietary supplement, Beer

YICHANG,China, Sept. 2, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast" or "Angel"), a listed high-tech yeast company in China, announced its nutritional R&D team has developed a new strain of yeast probiotic, Saccharomyces boulardiiBld-3 (S. boulardii Bld-3) , and an innovative production technology for the new product.

Key Points: 
  • YICHANG,China, Sept. 2, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast" or "Angel"), a listed high-tech yeast company in China, announced its nutritional R&D team has developed a new strain of yeast probiotic, Saccharomyces boulardiiBld-3 (S. boulardii Bld-3) , and an innovative production technology for the new product.
  • The patented yeast probiotic is designed to treat diarrhea and strengthen healthy digestive and immune systems in children and adults.
  • "Saccharomyces boulardii (S. boulardii) is a kind of probiotic that has been considered a crucial nutritional intervention in treating diarrhea.
  • In addition to S. boulardii Bld-3, Angel Yeast also produces Saccharomyces cerevisiae probiotic and other extensive ranges of functional yeast ingredients, with several new products in the pipeline including Kluyveromyces marxianus.

Angel Yeast Launches Patented Saccharomyces Boulardii Bld-3, a Strain of Yeast Probiotic Effective Against Diarrhea

Retrieved on: 
Thursday, September 2, 2021
CTO, Diarrhea, Saccharomyces cerevisiae, Chinese Journal, COVID-19, Gastroenteritis, Saccharomyces, Gastric acid, Probiotic, Angel, Human, Enzyme, Saccharomyces boulardii, Adult, Multimedia, Biofuel, Google Trends, Gastroenterology, Health, Dietary supplement, Beer

YICHANG,China, Sept. 2, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast" or "Angel"), a listed high-tech yeast company in China, announced its nutritional R&D team has developed a new strain of yeast probiotic, Saccharomyces boulardiiBld-3 (S. boulardii Bld-3) , and an innovative production technology for the new product.

Key Points: 
  • YICHANG,China, Sept. 2, 2021 /PRNewswire/ -- Angel Yeast Co., Ltd ("Angel Yeast" or "Angel"), a listed high-tech yeast company in China, announced its nutritional R&D team has developed a new strain of yeast probiotic, Saccharomyces boulardiiBld-3 (S. boulardii Bld-3) , and an innovative production technology for the new product.
  • The patented yeast probiotic is designed to treat diarrhea and strengthen healthy digestive and immune systems in children and adults.
  • "Saccharomyces boulardii (S. boulardii) is a kind of probiotic that has been considered a crucial nutritional intervention in treating diarrhea.
  • In addition to S. boulardii Bld-3, Angel Yeast also produces Saccharomyces cerevisiae probiotic and other extensive ranges of functional yeast ingredients, with several new products in the pipeline including Kluyveromyces marxianus.